Tissue Therapies Signs 2nd Contract with QSV

QSV Biologics has signed a second contract with Tissue Therapies Ltd. for the cGMP manufacture of clinical quantities of synthetic Vitroonectin and a single protein, chimeric form of VitroGro, called VitroGro-1. Tissue therapies will use these materials in preclinical and clinical trials early next year. Under the agreement QSV will be responsible for technology transfer and cGMP production in QSV’s licensed manufacturing facility. Terms of the final manufacturing contract have not been disclosed.

Dr. Graeme Macaloney, QSV’s founder and chief executive officer, said, “This represents repeat business with Tissue Therapies whereby we are now making several products for them. The high productivity cell culture manufacturing processes used for these products differ from earlier processes that we have been developing for them, but represent processes that our staff are experienced to deal with.”

Dr. Steven Mercer, Tissue Therapies chief executive officer, said, “QSV earned this extra business with their reliable, efficient and timely communications throughout all phases of delivering contract manufacturing services and their track record for delivering on time and within budget. VitroGro-1 represents a novel line of innovative chimeric products to be incorporated in to our VitroGro platform, while Vitronectin, will be used in other multiprotein formulations of VitroGro. I have great confidence that these ground-breaking products are in safe hands with QSV.”